<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />


<meta name="author" content="Your Name Here" />


<title>Step 3 (Identification) – Linking the HCV→AKI Causal Question to the Observed Data</title>

<script src="site_libs/header-attrs-2.29/header-attrs.js"></script>
<script src="site_libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="site_libs/bootstrap-3.3.5/css/cosmo.min.css" rel="stylesheet" />
<script src="site_libs/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="site_libs/navigation-1.1/tabsets.js"></script>
<link href="site_libs/highlightjs-9.12.0/textmate.css" rel="stylesheet" />
<script src="site_libs/highlightjs-9.12.0/highlight.js"></script>

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>

<style type="text/css">code{white-space: pre;}</style>
<script type="text/javascript">
if (window.hljs) {
  hljs.configure({languages: []});
  hljs.initHighlightingOnLoad();
  if (document.readyState && document.readyState === "complete") {
    window.setTimeout(function() { hljs.initHighlighting(); }, 0);
  }
}
</script>









<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-default  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">HOME</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li>
  <a href="RWE_tutorial.html">Introduction: TL Roadmap in RWE</a>
</li>
<li>
  <a href="step0.html">Causal roadmap and case study introduction</a>
</li>
<li>
  <a href="step1v2.html">Roadmap step 1-alt</a>
</li>
<li>
  <a href="step1a.html">Roadmap step 1a</a>
</li>
<li>
  <a href="step1b.html">Roadmap step 1b</a>
</li>
<li>
  <a href="step2.html">Roadmap step 2</a>
</li>
<li>
  <a href="step3.html">Roadmap step 3</a>
</li>
<li>
  <a href="step4.html">Roadmap step 4</a>
</li>
<li>
  <a href="step5.html">Roadmap step 5</a>
</li>
<li>
  <a href="PS_analysis.html">Propensity score matching analysis</a>
</li>
<li>
  <a href="appendix.html">Appendix</a>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">Step 3 (Identification) – Linking the
HCV→AKI Causal Question to the Observed Data</h1>
<h4 class="author">Your Name Here</h4>

</div>

<div id="TOC">
true
</div>

<div id="introduction-to-identification" class="section level2">
<h2>Introduction to <em>Identification</em></h2>
<p>Rigorous causal inference from observational data requires
translating the scientific questions posed in <strong>Step 1</strong>
into statistical parameters that are identifiable from the observed
data.</p>
<p>Before we can run any models we must answer two questions:</p>
<ol style="list-style-type: decimal">
<li><strong>What exact counterfactual quantity are we after?</strong>
(The <em>causal estimand</em> defined in step 1)</li>
<li><strong>Can that quantity be expressed with the data we
observe?</strong> (= <em>identifiability</em>)</li>
</ol>
<p>This <strong>identification step</strong> formally links the
counterfactual (causal) world to the factual world we can measure. Doing
so relies on three well-known assumptions—<strong>Consistency,
Conditional Exchangeability, and Positivity</strong>—described below in
the context of our revised primary and sensitivity estimands.</p>
<p># 3 Causal estimands expressed in mathematical notation ## 3.1
Primary – <em>Hypothetical no‑switch</em> risk at 90 days <em>“What
would the 90‑day cumulative risk of first AKI be if every patient stayed
on their initial regimen for the full 90 days?”</em></p>
<p><span class="math display">\[
\text{RD}_{\text{NS}} = E\![Y^{a=1,\;\text{no‑switch}}] \;-
                       E\![Y^{a=0,\;\text{no‑switch}}],
\quad
\text{RR}_{\text{NS}} = \frac{E\![Y^{1,\;\text{no‑switch}}]}
                             {E\![Y^{0,\;\text{no‑switch}}]}.
\]</span></p>
</div>
<div id="sensitivity-treatmentpolicy-itt-risk-at-90-days"
class="section level2">
<h2>3.2 Sensitivity – Treatment‑policy (ITT) risk at 90 days</h2>
<p><em>“What is the 90‑day AKI risk difference if clinicians simply
<em>start</em> SOF vs non‑SOF, allowing any subsequent
changes?”</em></p>
<p><span class="math display">\[
\text{RD}_{\text{ITT}} = E\![Y^{1}] - E\![Y^{0}],
\quad
\text{RR}_{\text{ITT}} = \frac{E\![Y^{1}]}{E\![Y^{0}]}.
\]</span></p>
</div>
<div id="identification-assumptions" class="section level1">
<h1>4 Identification assumptions</h1>
<p>To express those counterfactual risks with our data we need four
assumptions.</p>
<div id="consistency-sutva" class="section level2">
<h2>4.1 Consistency + SUTVA</h2>
<p>The outcome we observe equals the potential outcome under the regimen
actually received, and one patient’s treatment choice does not influence
another patient’s AKI risk.</p>
</div>
<div id="conditional-exchangeability-no-unmeasured-confounding"
class="section level2">
<h2>4.2 Conditional exchangeability (no unmeasured confounding)</h2>
<p><span class="math display">\[
Y^{a,\;\text{no‑switch}} \;\perp\!\!\!\perp\; A \mid W,
\quad
Y^{a} \;\perp\!\!\!\perp\; A \mid W.
\]</span></p>
<p>All factors that affect both initial regimen choice and AKI risk are
captured in $W$.</p>
</div>
<div id="positivity" class="section level2">
<h2>4.3 Positivity</h2>
<p><em>Treatment positivity</em> — every covariate pattern with positive
probability has some chance of receiving either regimen:</p>
<p><span class="math display">\[
0 &lt; P(A=a\mid W) &lt; 1.
\]</span></p>
<p><em>Time‑varying positivity</em> (primary estimand) — no
regimen‑and‑history pattern forces an immediate switch/discontinuation
over 0–90 d.</p>
</div>
<div id="independent-censoring-primary-estimand" class="section level2">
<h2>4.4 Independent censoring (primary estimand)</h2>
<p>After adjusting for observed history <span
class="math inline">\(\bar{L}(t)\)</span> the chance of remaining
uncensored is unrelated to the counterfactual outcome:</p>
<p><span class="math display">\[
Y^{a,\;\text{no‑switch}} \;\perp\!\!\!\perp\; C(t) \mid A=a,\;
\bar{L}(t),\, W.
\]</span></p>
<p>We relax this by modelling the switching/death hazard and using
inverse‑probability‑of‑censoring weights (IPCW) inside the TMLE.</p>
</div>
</div>
<div id="observeddata-functionals-the-gformula" class="section level1">
<h1>5 Observed‑data functionals (the <em>g‑formula</em>)</h1>
<div id="itt-estimand" class="section level2">
<h2>5.1 ITT estimand</h2>
<p><span class="math display">\[
E\![Y^{a}] = E_{W}\bigl[\,E(Y\mid A=a, W)\bigr].
\]</span></p>
</div>
<div id="noswitch-estimand-with-ipcw" class="section level2">
<h2>5.2 No‑switch estimand with IPCW</h2>
<p>Define the weight for subject <em>i</em> through 90 d:</p>
<p><span class="math display">\[
W_{i}(90) =
\prod_{t\le 90}\frac{P\{C_{i}(t)=0\mid A_{i}=a, W_{i}\}}
                        {P\{C_{i}(t)=0\mid A_{i}=a, \bar{L}_{i}(t),
W_{i}\}}.
\]</span></p>
<p>Then</p>
<p><span class="math display">\[
E\![Y^{a,\;\text{no‑switch}}] = E\bigl[\,W_{i}(90)\,Y_{i}\bigr].
\]</span></p>
<p>Our one‑step <em>continuous‑time</em> TMLE (implemented via the
<strong><code>concrete</code></strong> package) directly targets these
weighted risks, giving double‑robustness: correct either the outcome
model <strong>or</strong> the censoring model is sufficient for
consistent estimation.</p>
</div>
</div>
<div id="why-these-assumptions-are-plausible-or-not-in-claims-data"
class="section level1">
<h1>6 Why these assumptions are plausible (or not) in claims data</h1>
<ul>
<li><strong>Consistency / SUTVA:</strong> Each patient’s AKI diagnosis
is determined by their own regimen and physiology; spill‑over is
unlikely.</li>
<li><strong>Exchangeability:</strong> We include rich baseline medical
history from the claims data (CKD stage, eGFR, liver disease, etc.).
Residual confounding remains possible if, for instance, prescriber
preference correlates with unmeasured kidney function.</li>
<li><strong>Positivity:</strong> Both SOF and non‑SOF regimens are
widely used across all patient profiles in commercial and Medicare
claims, but we will check overlap via propensity‑score diagnostics.</li>
<li><strong>Independent censoring:</strong> Switching is often triggered
by rising creatinine, so naïve censoring would be informative. IPCW
mitigates this by modelling the switching hazard as a function of
observed labs and comorbidities.</li>
</ul>
</div>
<div id="takehome-message-for-pharmacoepidemiologists"
class="section level1">
<h1>7 Take‑home message for pharmacoepidemiologists</h1>
<p>The Identification step distils <em>clinical intent</em> into a pair
of mathematically precise contrasts and spells out exactly what we must
believe about the data for those contrasts to be recoverable. Once these
assumptions are on the page, colleagues and reviewers can scrutinise
them, and the subsequent estimation step (Step 3) flows in a straight
line from the formulas above.</p>
<p><em>Next up:</em> we implement doubly‑robust estimation of these
risks with continuous‑time TMLE (<code>concrete</code>) and evaluate how
sensitive the conclusions are to the assumptions listed here.</p>
<p>#Old</p>
<div id="statistical-model-setup" class="section level3">
<h3>2.2 Statistical Model Setup</h3>
<p>We begin by specifying the observed‐data structure for each study
subject:</p>
<table>
<colgroup>
<col width="19%" />
<col width="80%" />
</colgroup>
<thead>
<tr class="header">
<th>Symbol</th>
<th>Description (HCV → AKI example)</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong><span class="math inline">\(W\)</span></strong></td>
<td>Baseline covariates: age, sex, chronic kidney disease (CKD),
diabetes, baseline eGFR, cirrhosis, healthcare utilisation, etc.</td>
</tr>
<tr class="even">
<td><strong><span class="math inline">\(A\)</span></strong></td>
<td>Indicator of the initial antiviral regimen (1 =
sofosbuvir-containing, 0 = non-sofosbuvir).</td>
</tr>
<tr class="odd">
<td><strong><span class="math inline">\(T\)</span></strong></td>
<td>Follow-up time (in days) to either first AKI, censoring, or study
end.</td>
</tr>
<tr class="even">
<td><strong><span class="math inline">\(\Delta\)</span></strong></td>
<td>Event type: 1 = AKI, 0 = right censoring. For the <strong>primary
dataset</strong> we treat <em>regimen switching</em> as censoring; for
the <strong>ITT dataset</strong> we ignore switching.</td>
</tr>
</tbody>
</table>
<p>The individual-level observed data vector is therefore<br />
<span class="math display">\[
O \;=\; (W,\,A,\,T,\,\Delta)\;,
\]</span> and the statistical model is the non-parametric class<br />
<span class="math display">\[
\mathcal{M} \;=\; \bigl\{P(O)\bigr\},
\]</span> i.e., all distributions consistent with the data schema above
(no further parametric restrictions).</p>
<hr />
</div>
<div id="causal-parameters-estimands" class="section level3">
<h3>2.3 Causal Parameters (Estimands)</h3>
<ul>
<li><p><strong>Primary estimand – Hypothetical “no-switch” risk
difference / risk ratio</strong><br />
<em>Counterfactual contrast of 90-day AKI risk if <strong>every patient
remained on the initial regimen for the full 90
days</strong>.</em><br />
<span class="math display">\[
\text{RD}_{\!\text{NS}} \;=\; E\!\bigl[Y^{a=1,\; \text{no-switch}}
\bigr] -
                             E\!\bigl[Y^{a=0,\; \text{no-switch}}
\bigr],
\qquad\;
\text{RR}_{\!\text{NS}} \;=\;
\frac{E\!\bigl[Y^{a=1,\; \text{no-switch}}\bigr]}
     {E\!\bigl[Y^{a=0,\; \text{no-switch}}\bigr]}.
\]</span></p></li>
<li><p><strong>Sensitivity estimand – Treatment-policy (ITT) risk
difference / risk ratio</strong><br />
<em>Counterfactual contrast of 90-day AKI risk when patients are
<strong>started</strong> on SOF vs non-SOF, <strong>allowing real-world
switching and discontinuation</strong>.</em><br />
<span class="math display">\[
\text{RD}_{\!\text{ITT}} \;=\; E\!\bigl[Y^{a=1}\bigr] -
                               E\!\bigl[Y^{a=0}\bigr],
\qquad\;
\text{RR}_{\!\text{ITT}} \;=\;
\frac{E\!\bigl[Y^{a=1}\bigr]}
     {E\!\bigl[Y^{a=0}\bigr]}.
\]</span></p></li>
</ul>
<hr />
</div>
<div id="key-identification-assumptions" class="section level3">
<h3>2.4 Key Identification Assumptions</h3>
<div id="consistency" class="section level4">
<h4>2.4.1 Consistency</h4>
<p>For each subject the observed outcome equals the potential outcome
under the treatment actually received: <span class="math display">\[
Y \;=\; A\,Y^{a=1} + (1-A)\,Y^{a=0}.
\]</span> In the primary analysis we further assume that, had switching
been prevented, each individual’s potential outcome <span
class="math inline">\(Y^{a,\;\text{no-switch}}\)</span> equals the
outcome we would observe <em>if</em> they indeed remained on their
initial regimen.</p>
</div>
<div id="conditional-exchangeability-ignorability"
class="section level4">
<h4>2.4.2 Conditional Exchangeability (Ignorability)</h4>
<p>After adjusting for baseline covariates <span
class="math inline">\(W\)</span>, initial regimen choice is as good as
random: <span class="math display">\[
Y^{a,\;\text{no-switch}} \;\perp\!\!\!\perp\; A \;\bigl|\, W,
\qquad
Y^{a} \;\perp\!\!\!\perp\; A \;\bigl|\, W.
\]</span> That is, no unmeasured baseline confounders influence both
treatment choice and AKI risk.</p>
</div>
<div id="positivity-1" class="section level4">
<h4>2.4.3 Positivity</h4>
<p>Every covariate pattern observed in the data must have a non-zero
probability of receiving either regimen: <span class="math display">\[
0 \;&lt;\; P(A=a \mid W)\;&lt;\;1
\quad\text{for all } a\in\{0,1\},\; W \text{ with } P(W)&gt;0.
\]</span></p>
</div>
<div id="independent-censoring-primary-estimand-only"
class="section level4">
<h4>2.4.4 Independent Censoring (Primary estimand only)</h4>
<p>For the hypothetical no-switch contrast we treat switching, death,
and disenrolment as censoring events. Identification therefore
additionally requires <span class="math display">\[
Y^{a,\;\text{no-switch}} \;\perp\!\!\!\perp\; C \;\bigl|\, A, W,
\]</span> where <span class="math inline">\(C\)</span> is the censoring
indicator. In practice we relax this assumption by using
<strong>inverse-probability-of-censoring weighting (IPCW)</strong>
within the continuous-time TMLE so that censoring can depend on measured
time-varying information.</p>
<hr />
</div>
</div>
<div id="identification-formulae" class="section level3">
<h3>2.5 Identification Formulae</h3>
<p>Under the assumptions above, both estimands can be expressed as
purely statistical functionals of the observed-data distribution. For
example, the g-formula for the ITT risk is <span class="math display">\[
E\bigl[Y^{a}\bigr]
  \;=\; E_{W}\!\bigl[\,E(Y \mid A=a, W)\bigr].
\]</span> The analogous expression for the no-switch estimand replaces
the inner expectation with the counterfactual risk under a sustained
exposure, which we evaluate using one-step TMLE implemented in the
<strong><code>concrete</code></strong> package.</p>
<hr />
</div>
<div id="practical-challenges" class="section level3">
<h3>2.6 Practical Challenges</h3>
<ul>
<li><p><strong>Informative censoring (primary estimand).</strong><br />
Because regimen switching may be triggered by early signs of
nephro-toxicity, simple censoring is likely informative. IPCW within
TMLE adjusts for this, but relies on correctly modelling the switching
hazard and on measured covariates capturing all reasons for
switching.</p></li>
<li><p><strong>Measurement error in AKI coding.</strong><br />
AKI identified from claims may misclassify events. Planned sensitivity
analyses will repeat estimation with stricter ICD definitions (e.g.,
dialysis, hospitalisation) to gauge robustness.</p></li>
</ul>
<hr />
</div>
<div id="summary" class="section level3">
<h3>2.7 Summary</h3>
<p>By redefining the <strong>primary estimand</strong> as the 90-day
risk difference/ratio <em>under a hypothetical no-switch strategy</em>,
and retaining the original ITT contrast as a key <strong>sensitivity
analysis</strong>, we align the identification step with our updated
scientific objectives. All subsequent estimation and inference will
explicitly rely on the assumptions enumerated above and use the
continuous-time TMLE framework (<code>concrete</code>) to obtain
doubly-robust estimates of both causal contrasts.</p>
<p>#Old</p>
</div>
<div id="introduction-to-identification-1" class="section level2">
<h2>Introduction to Identification</h2>
<p>Causal inference from observational data relies on translating causal
questions into identifiable statistical parameters. The process of
<strong>causal identification</strong> formally connects causal
parameters to observed data distributions. It relies on three
fundamental assumptions: 1. <strong>Consistency</strong> 2.
<strong>Conditional Exchangeability (Ignorability)</strong> 3.
<strong>Positivity</strong> We describe each assumption in detail below,
linking explicitly to the causal question defined in Step 1. # 2.2
Statistical Model Setup We first clearly specify the observed data
structure and statistical model. In our AKI-HCV example, we define each
observed data element: - <strong>Baseline covariates (</strong><span
class="math inline">\(W\)</span>): Age, sex, chronic kidney disease
(CKD), diabetes, baseline eGFR, liver disease status, and healthcare
utilization. - <strong>Treatment (</strong><span
class="math inline">\(A\)</span>): Initial regimen choice (SOF
vs. non-SOF DAA). - <strong>Outcome (</strong><span
class="math inline">\(Y\)</span>): Binary indicator for AKI occurrence
within 90 days. - <strong>Censoring (</strong><span
class="math inline">\(C\)</span>): Indicators for loss to follow-up due
to death, regimen switching, or insurance disenrollment. Formally, each
participant’s observed data are: <span class="math display">\[ O = (W,
A, C, Y) \]</span> Our statistical model, denoted as <span
class="math inline">\(\mathcal{M}\)</span>, is the nonparametric
statistical model comprising all distributions consistent with the data
structure above: <span class="math display">\[ \mathcal{M} = \{P(O)\}
\]</span> No parametric assumptions are made yet; flexibility is
maintained. # 2.3 Defining the Causal Parameter (Estimand) We now
restate the primary causal parameter (estimand) selected in Step 1: -
<strong>Estimand:</strong> Risk difference (RD) and risk ratio (RR)
comparing SOF-containing regimen versus non-SOF regimen at 90 days,
under the <strong>as-treated, censor-at-switch</strong> strategy. In
causal notation, this is expressed in terms of potential outcomes <span
class="math inline">\(Y^{a}\)</span>: - <strong>Risk difference
(RD)</strong>: <span class="math display">\[ \text{RD} = E[Y^{a=1}] -
E[Y^{a=0}] \]</span> - <strong>Risk ratio (RR)</strong>: <span
class="math display">\[ \text{RR} = \frac{E[Y^{a=1}]}{E[Y^{a=0}]}
\]</span> This contrasts the AKI risk under universal assignment to
SOF-containing DAAs versus universal assignment to non-SOF DAAs. # 2.4
Key Identification Assumptions We now explicitly define and discuss the
identification assumptions required. ## 2.4.1 Consistency
<strong>Consistency</strong> ensures the observed outcome corresponds
exactly to the potential outcome under the regimen actually received: -
Formally: <span class="math display">\[ Y = A \cdot Y^{a=1} + (1 - A)
\cdot Y^{a=0} \]</span> - <strong>Interpretation</strong>: The observed
AKI status must exactly reflect the causal effect of the actual regimen
initiated. ## 2.4.2 Conditional Exchangeability (Ignorability)
<strong>Conditional Exchangeability</strong> states no unmeasured
confounding after conditioning on <span
class="math inline">\(W\)</span>: - Formally: <span
class="math display">\[ Y^{a} \perp A \mid W \]</span> -
<strong>Interpretation</strong>: There are no hidden baseline factors
influencing both initial regimen choice and AKI risk. Practically, this
means we’ve measured sufficient baseline covariates to eliminate
confounding bias. ## 2.4.3 Positivity (Overlap)
<strong>Positivity</strong> requires nonzero probability of receiving
each treatment for all relevant subgroups defined by <span
class="math inline">\(W\)</span>: - Formally: <span
class="math display">\[ 0 &lt; P(A=a|W) &lt; 1 \quad\text{for all
relevant } W \]</span> - <strong>Interpretation</strong>: For every type
of patient considered in the study, treatment choice (SOF vs. non-SOF)
must be realistically possible. Violation of positivity creates problems
for causal estimation; thus, careful assessment and diagnostics (e.g.,
checking propensity scores distributions) will be performed in Step 4. #
2.5 Identification Result (G-computation Formula) Under these three
assumptions, we formally identify the causal parameter as a purely
statistical quantity (g-formula): - The causal estimand can be expressed
as: <span class="math display">\[ E[Y^a] = E_W\left[E(Y|A=a, W)\right]
\]</span> - Therefore, the risk difference (RD) is explicitly: <span
class="math display">\[ RD = E_W\left[E(Y|A=1,W)\right] -
E_W\left[E(Y|A=0,W)\right] \]</span> - Similarly, the risk ratio (RR)
is: <span class="math display">\[ RR =
\frac{E_W\left[E(Y|A=1,W)\right]}{E_W\left[E(Y|A=0,W)\right]} \]</span>
In practice, estimation (Steps 3–4) will rely on methods such as
targeted maximum likelihood estimation (TMLE) and Super Learner to
flexibly estimate these conditional expectations. # 2.6 Practical
Considerations and Challenges ## 2.6.1 Informative Censoring Our
estimand (as-treated censoring) assumes censoring events (e.g., regimen
switching, death, disenrollment) are non-informative, conditional on
measured covariates. Violations—called informative censoring—can bias
results. - <strong>Assessment:</strong> Sensitivity analyses will
evaluate robustness against censoring violations, including
inverse-probability-of-censoring weighting (IPCW). ## 2.6.2 Measurement
Error AKI defined by ICD codes or claims data may suffer measurement
error: - <strong>Assessment:</strong> Sensitivity analyses using
alternative outcome definitions (e.g., hospitalization-required AKI,
dialysis initiation) help ensure results’ robustness. # 2.7 Summary of
Identification Clearly stating the identification assumptions upfront
provides transparency and allows critical evaluation. Subsequent steps
(estimation, sensitivity analyses) directly rely on these assumptions’
validity.</p>
</div>
</div>




</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
